Filing Details

Accession Number:
0001104659-22-075361
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-06-28 19:00:41
Reporting Period:
2022-06-27
Accepted Time:
2022-06-28 19:00:41
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1326190 Altimmune Inc. ALT Pharmaceutical Preparations (2834) 202726770
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1705905 Scot M Roberts C/O Altimmune, Inc., 910 Clopper Road,
Suite 201S
Gaithersburg, MD 20878
Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $0.0001 Acquisiton 2022-06-27 25,583 $1.92 43,283 No 4 M Direct
Common Stock, Par Value $0.0001 Acquisiton 2022-06-27 11,769 $2.60 55,052 No 4 M Direct
Common Stock, Par Value $0.0001 Disposition 2022-06-27 37,352 $12.00 17,700 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock, Par Value $0.0001 Stock Options (option to buy) Disposition 2022-06-27 25,583 $0.00 61,400 $1.92
Common Stock, Par Value $0.0001 Stock Options (option to buy) Disposition 2022-06-27 11,769 $0.00 30,000 $2.60
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
35,817 2030-01-02 No 4 M Direct
18,231 2029-01-02 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock, Par Value $0.0001 15 Indirect Shares held by spouse of Reporting Person
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.0000 to $12.0250, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  3. Twenty-five percent of the shares underlying the option become vested and exercisable on January 2, 2021 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following January 2, 2021, subject to the reporting person's continued service through the applicable vesting date.
  4. Twenty-five percent of the shares underlying the option become vested and exercisable on the first anniversary of the Grant Date and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following the one-year anniversary of the Grant Date, in each case, generally subject to the reporting person's continued service through the applicable vesting date.